0Y3M.LSE Prothena Corp. PLC
- Market cap
- -
- P/E
- 6.2x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 0Y3M.LSE undervalued?
Graham numberThe Graham number of Prothena Corp. PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Prothena Corp. PLC fundamental analysis
No fundamental analysis for Prothena Corp. PLC yet.
Prothena Corp. PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Prothena Corp. PLC
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial fo…
Full company profileProthena Corp. PLC financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Prothena Corp. PLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.06M | 27.5M | 955K | 814K | 853K | - | - | - |
| Operating Income | -160M | -155M | -159M | -85.7M | -113M | - | - | - |
| Net Income | -160M | -153M | -156M | -77.7M | -111M | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | 460M | 496M | 499M | 419M | 333M | - | - | - |
| Total Liabilities | 94.6M | 89.1M | 176M | 146M | 149M | - | - | - |
| Shareholders' Equity | 365M | 407M | 323M | 273M | 184M | - | - | - |
| Cash & Short-term Investments | 387M | 418M | 428M | 376M | 295M | - | - | - |
| Total Debt | - | 51.5M | 49.9M | - | - | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -116M | -131M | -28.3M | -53.0M | -80.4M | 92.6M | -109M | - |
| Capital Expenditure | 16.6M | 3.63M | 1.77M | 555K | 196K | 575K | 464K | 0.00 |
| Ratios | ||||||||
| ROE | -43.8% | -37.6% | -48.2% | -28.5% | -60.4% | - | - | - |
| ROA | -34.8% | -30.9% | -31.2% | -18.5% | -33.4% | - | - | - |
| Net Profit Margin | -15,176.1% | -556.8% | -16,297.9% | -9,542.6% | -13,029.8% | - | - | - |
| Debt to Equity | - | 0.13x | 0.15x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Prothena Corp. PLC dividends
Prothena Corp. PLC has not paid dividends in the last 9 fiscal years.
Who owns Prothena Corp. PLC
- Insiders 23.96%
- Institutions 76.04%
- Public & others 0.00%
- Free float 33.4M
Prothena Corp. PLC company profile
- Company name
- Prothena Corp. PLC
- Ticker
- 0Y3M.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 67
- Fiscal year end
- December
- Address
- 77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60
- Phone
- 353 1 236 2500
- Website
- prothena.com
About Prothena Corp. PLC
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Prothena Corp. PLC management
9- Dr. Gene G. Kinney Ph.D.President, CEO & Director · born 1969
- Mr. Tran B. Nguyen M.B.A.Chief Financial Officer · born 1974
- Mr. Brandon S. SmithChief Operating Officer · born 1975
- Dr. Wagner M. Zago Ph.D.Chief Scientific Officer · born 1973
- Ms. Karin L. Walker CPAChief Accounting Officer & Controller · born 1963
- Mr. Mark C. Johnson C.F.A.Vice President of Investor Relations
- Mr. Michael J. IsaacsGeneral Counsel & Corporate Secretary
- Phillip DolanSr. Director & Head of Exploratory Research
- Ms. Annie Evans KingstonChief Strategy Officer